A Close Look at Growblox Sciences Inc (OTCMKTS:GBLX)


Growblox Sciences Inc (OTCMKTS:GBLX) has been trading on light volume just over its established $20 support levels.  The stock popped earlier this year as well as at the end of last year to %0.45 highs during the last mj rush to highs of $0.65.

GBLX started trading as Growblox Sciences Inc in April of last year after the name change from Signature Exploration and Production Corp. Prior to that GBLX traded as Flagstick Ventures, Inc as well as Diabetic Treatment Centers of America, Inc.

Growblox Sciences Inc (OTCMKTS:GBLX) is a biotechnology research and development company focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies that target a variety of medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.

GB Sciences’ pioneering self-contained growing unit isolates and protects the plants growing inside while generating ideal growing environments to ensure high quality, purity, and consistency.

TissueBLOX™ – The tissue culture incubator is programmed to regulate lighting, temperature, and humidity to facilitate cell multiplication and the formation of embryos and shoots from the sterile explants.

GrowBLOX™ – GB Sciences’ pioneering self-contained growing unit that isolates and protects the plants growing inside while generating ideal growing environments

CureBLOX™ – The CureBLOX™ module enables us to eliminate the risk of mold growth and ensure that the chemical profile of our products is consistent from harvest to harvest.

GB Sciences ApotheCAREians – Highly trained and certified ApotheCAREians work with patients to determine their medical needs, identify therapeutic products, install GB Sciences’ app on their hand-held devices, and demonstrate how to place orders.

To Find out the inside Scoop on GBLX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ApotheCAREians are patient-care professionals who know more about cannabinoid therapy than most physicians, since doctors are rarely trained in cannabinoid therapy. They understand the science of cannabis and can help patients choose the cannabinoid therapy products that will provide the most effective treatment for their particular medical conditions.

On July 17 GBLX announced it has signed a Consulting Services Agreement with Worldwide Clinical Trials, Inc. to evaluate the company’s intellectual property portfolio and to assist with pre-IND planning for its proprietary cannabis-based formulations. These pre-IND consulting services will be performed by the Chief Medical and Scientific Officer (CMSO) of Worldwide, Michael F. Murphy, MD, PhD, as the representative of an extended Worldwide team. Dr. Murphy has participated in the IND application process for multiple small molecules and biologics with 19 therapeutic targets, across five divisions of the FDA. Dr. Murphy was also the Clinical Research and Excellence (CARE) Lifetime Achievement Award recipient for 2017. The award is presented annually to an extraordinary individual with exceptional contributions and a consistent history of service to the clinical research industry throughout their career.

According to Dr. Murphy, “Current research and development practices emphasize the importance of coordinated activity by industry, academia, and contract research organizations in the evaluation of innovative products, like those of GB Sciences. The process enhances program efficiency, facilitates the integration of the perspective of diverse stakeholders early in clinical development, and is a testament to GB Sciences’ strategic vision for the development of their portfolio of products. Worldwide is very pleased to be a contributor to that process, and the state-of-the-art technology which it reflects.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $28 million market valuation GBLX has little assets or debt and no revenues to date. But this is an exciting story developing in small caps; the Company has a valuable intellectual property portfolio and is developing state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis and has recently announced a number of exciting new initiatives including . We will be updating on GBLX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GBLX.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in GBLX either long or short and we have not been compensated for this article.


Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.